Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EKSO BIONICS ( (EKSO) ) has issued an update.
On October 28, 2025, Ekso Bionics entered into a securities purchase agreement with institutional investors to sell 769,490 shares of its common stock at $4.81 per share in a registered direct offering. The offering is expected to close by October 30, 2025, with net proceeds of approximately $3.2 million intended for general corporate purposes, including research and development, administrative costs, and strategic initiatives. The company also entered into a placement agency agreement with Lake Street Capital Markets, LLC, which will receive a 6% cash fee and a warrant to purchase additional shares.
The most recent analyst rating on (EKSO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.
Spark’s Take on EKSO Stock
According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral.
EKSO BIONICS’ overall stock score is primarily impacted by its financial performance, characterized by persistent losses and reliance on external financing. Technical analysis suggests potential stabilization, but valuation remains a concern due to negative earnings. The earnings call underscored significant financial challenges, despite some positive developments.
To see Spark’s full report on EKSO stock, click here.
More about EKSO BIONICS
Average Trading Volume: 52,284
Technical Sentiment Signal: Sell
Current Market Cap: $13.77M
For detailed information about EKSO stock, go to TipRanks’ Stock Analysis page.